



KEY FINANCIAL HIGHLIGHTS OF 2018-19

TOTAL REVENUE
₹195,636
MILLION

EBITDA
₹39,519
MILLION

PAT
₹23,647
MILLION

EPS
₹40.36

CONTENTS

COMPANY OVERVIEW

- 02 Introducing Aurobindo Pharma
- 04 Worldwide Presence
- 06 Business Overview
- 08 Key Performance Indicators
- 10 Vice Chairman's Review
- 12 Managing Director's Message
- 14 Business Model
- 16 Lead with a Range of Products
- 20 Expand into New Areas
- 24 Attain Capabilities and Strengthening Compliance
- 28 Promote an Execution-oriented Growth Mindset
- 30 Board of Directors
- 32 Environment, Health and Safety
- 34 Corporate Social Responsibility

STATUTORY REPORTS

- 36 Notice
- 48 Board's Report
- 60 Management Discussion and Analysis
- 68 Management of Risks
- 78 Business Responsibility Report
- 116 Report on Corporate Governance

FINANCIAL STATEMENTS

- 134 Standalone Financial Statements
- 201 Consolidated Financial Statements



<https://www.aurobindo.com/investors/results-reports-presentations/annual-reports/>

As a well-integrated pharma company, LEAP, for us, has a broader connotation that encompasses every aspect of the business – from products, processes to global capabilities, compliance aspects and people. Within a short span of three decades, we have emerged as the 10th largest global generic company, in terms of revenue.

We have accomplished this distinction by offering a diversified product basket, foraying into new therapeutic areas, exploring new markets and expertise both organically & inorganically.

LEAP, an encapsulation of our key differentiators that sets us apart in a constantly evolving and hyper-competitive market environment.



Our business has grown sustainably over all these years as we have always followed the strategy of being present in a wide range of product basket in every segment that we enter. This has helped us scale to our current size.



We have also been eager to expand into new therapeutic areas and segments, wherever we have capabilities. We are strengthening our product basket by creating a range of products in a host of new segments such as oncology, hormones, dermatology, respiratory, biosimilars, vaccines, peptides and depot injections.



To grow sustainably, we have acquired a rich repertoire of capabilities both organically and inorganically, while further strengthening our existing and new units to produce quality products.



At Aurobindo Pharma, we believe that one of our biggest strength lies in execution. It is our ability to take on projects and seamlessly execute them within a limited timeframe meeting all the fundamental requirements including compliance that has brought us success across geographies, markets and products. As we grow, we are increasingly embedding our capabilities across all facets of our business to support our fast-paced execution strategy.

These differentiators are integral to our DNA and help us LEAP to the next wave of growth and sustainability.

Scaling up to LEAP ahead

We, at Aurobindo Pharma, commenced our journey in 1986 with a mission to become the most valued partner to the global pharma fraternity by continuously researching, developing and manufacturing a wide range of pharmaceutical products for patients in need.

We are the second largest generic company in the US in terms of prescriptions dispensed and rank among the top 10 generic companies in eight out of top the 11 countries we operate in Europe

As one of India's largest vertically integrated pharmaceutical companies, our strength lies in developing quality Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). These products are manufactured across our facilities, which have been inspected by various regulatory authorities such as the USFDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, and ANVISA Brazil.

We have established our foothold in key therapeutic segments such as Central Nervous System (CNS),

Cardiovascular System (CVS), Antiretrovirals, Diabetics, Anti-Allergies, Gastroenterology and Antibiotics, and are expanding into Speciality Generics.

Our research team helps us to commercialise cost-effective and quality products. Our Research & Development (R&D) initiatives are increasingly directed towards difficult-to-develop niche products, which requires bioequivalence studies or clinical trials.

Taking a long-term perspective, we focus on developing complex molecules and adopting new technologies to improve the lives of millions of patients globally.



10th

**LARGEST GENERIC COMPANY BY
REVENUES GLOBALLY**

**2ND LARGEST
LISTED INDIAN
PHARMACEUTICAL
COMPANY BY REVENUES**

**2ND LARGEST
GENERIC COMPANY BY
PRESCRIPTIONS DISPENSED
IN THE US**

**AMONGST TOP 10
GENERIC COMPANIES IN 4
OUT OF TOP 5 EUROPEAN
MARKETS**

22,000+
EMPLOYEES
GLOBALLY

7
R&D CENTRES WITH
A TEAM OF 1,600+
PROFESSIONALS

US\$2.8 Bn
IN REVENUES FOR
2018-19

34 COUNTRIES
FRONTEND PRESENCE WITH
PRODUCTS EXPORTED TO
155 NATIONS

33 BILLION+
DIVERSE DOSAGE FORMS
MANUFACTURED
IN 2018-19

27
MANUFACTURING
FACILITIES
WORLDWIDE

Strengthening global prominence

- | | |
|------------------|-----------------------|
| 01. Australia | 18. Thailand |
| 02. Hong Kong | 19. Czech |
| 03. Russia | 20. Myanmar |
| 04. Belgium | 21. Uganda |
| 05. Italy | 22. Ethiopia |
| 06. South Africa | 23. Netherlands |
| 07. Brazil | 24. UK |
| 08. Japan | 25. France |
| 09. Spain | 26. Poland |
| 10. Canada | 27. Ukraine |
| 11. Kenya | 28. GCC (Dubai, Oman) |
| 12. Sudan | 29. Portugal |
| 13. China | 30. USA |
| 14. Malta | 31. Germany |
| 15. Tanzania | 32. Romania |
| 16. Colombia | 33. Vietnam |
| 17. Mexico | 34. India |

**9TH LARGEST
GENERIC COMPANY
AS PER SALES**

10

30

17

**3 FORMULATION
FACILITIES AND
2 R&D CENTRES**

**PORTFOLIO MIX IS
COMPLEMENTED WITH
THE INTRODUCTION OF
HIGH-VALUE PRODUCTS**

16

07

**ONE
FORMULATION
FACILITY**

2nd Largest

GENERIC COMPANY AS PER
Rx DISPENSED IN THE USA

AMONGST
Top 10

GENERIC PLAYERS IN FRANCE,
GERMANY, PORTUGAL, UK, ITALY,
CZECH REPUBLIC, NETHERLANDS
AND BELGIUM

Company Overview

Statutory Reports

Financial Statements

ONE
FORMULATION
FACILITY

ONE
FORMULATION
FACILITY

11 API AND INTERMEDIATE PLANTS
10 FORMULATION FACILITIES
5 R&D CENTRES

Map not to scale


Building on our global expertise

FORMULATIONS

US



- Our prescription market share in oral solid improved to 7.0% for MAT March 2019 from 5.3% in the corresponding previous year
- Witnessed growth across segments including orals, injectables, over the counter (OTC) and dietary supplements
- Entered the branded oncology market with a range of recognised products
- Filed 63 ANDAs with the USFDA, including 21 injectables, 3 dermatology and 2 nasals



REVENUE
₹90,307
MILLION

EUROPE



- Among the top ten generic companies in eight out of the 11 countries we operate in
- Acquired Apotex Inc's operations in five European countries, helped foray into Poland and the Czech Republic and augment presence in Spain, Netherlands and Belgium
- Operates across 11 countries with full-fledged pharmacy, hospital and tender sales infrastructure
- Portfolio expansion through the launches of targeted Day 1 products, oncology range, hormones and niche low-volume injectables and orals



REVENUE
₹49,602
MILLION

GROWTH MARKETS



- Focused on key markets of Canada, Brazil and South Africa
- Among Canada's top 10 generic companies
- Growth to be driven by registering more products in oncology and specialty injectables
- Joint venture with Shandong Luoxin to set up a manufacturing plant in China



REVENUE
₹11,937
MILLION

ANTIRETROVIRAL DRUGS (ARVS)



- Strategic focus on garnering business from tenders floated by multilateral organisations
- Pick-up in sales from Dolutegravir triple combination product
- Awarded tender from South African government, supplies to begin from 2019-20

5%

REVENUE
₹9,725
MILLION

API



- Strategic in terms of vertical integration with 70% of API being sourced internally
- To focus on moving up the value chain with more complex products
- Additional investments being made to scale up capacities
- 242 Drug Master files (DMFs) filed with USFDA as on 31st March 2019

17.4%

REVENUE
₹34,030
MILLION

Delivering sustained growth

REVENUE (₹ IN MILLION)

12.7%

2018-19	195,636
2017-18	164,998
2016-17	150,899
2015-16	139,552
2014-15	121,205

EBITDA (₹ IN MILLION)

11.4%

2018-19	39,519
2017-18	37,885
2016-17	34,343
2015-16	31,881
2014-15	25,636

EBITDA MARGIN (%)

2018-19	20.2
2017-18	23.0
2016-17	22.8
2015-16	22.8
2014-15	21.2

PAT (₹ IN MILLION)

10.7%


2018-19	23,647
2017-18	24,232
2016-17	23,017
2015-16	20,251
2014-15	15,758

NET DEBT/EQUITY

2018-19	0.36
2017-18	0.30
2016-17	0.30
2015-16	0.58
2014-15	0.77

NET DEBT/EBITDA

2018-19	1.27
2017-18	0.93
2016-17	0.83
2015-16	1.33
2014-15	1.55

 5 year CAGR